Precision BioSciences Inc (DTIL)

[rtrstock]

https://www.defenseworld.net/2022/08/06/precision-biosciences-dtil-set-to-announce-quarterly-earnings-on-monday.html

Quarterly Earnings Monday

Waiting for much much higher...like this alot

[swampboots]

DTIL 1.75 Monday it will command more vol.

[swampboots]

DTIL 1.60 , staying in 50 day channel, want some morei 1.50's.

[swampboots]

DTIL 1.70 sold 1/2 as went down more than went up o these yoyo moves, so equals same if it goes dow for me before it makes its move.

[swampboots]

DTIL 1.70 OK its ready to do the 2!

[swampboots]

DTIL 1.60 now its read with technical backing.

[swampboots]

DTIL 1.52 small creep to highest share hold, waiting for spike but want to duck any bad earnings surprises next week.

[swampboots]

DTIL 1.42 lowest able but sold some 1.53..got killed yesterday buying low and not being able to sell to buy AMTD, nuts!

[swampboots]

DTIL: while waiting of excelled explanation:
https://www.healio.com/news/hematology-oncology/20210810/onestep-geneediting-technique-opens-door-to-safe-effective-offtheshelf-car-t-cells#:~:text=ARCUS%20is%20a%20proprietary%20platform,of%20design%20or%20fast%20turnaround

[swampboots]

DTIL 1.50 rebuy, want 1.40's for end play.

[swampboots]

DTIL :
Soon-Shiong CEO of Nanthealth became a billionaire after selling two drug companies: APP Pharmaceuticals and Abraxis BioScience. He sold APP to Fresenius Medical Care for $4.6 billion in 2008, and Abraxis to Celgene for $2.8 billion in 2010. He owns the Los Angeles Times and a 4.5% stake in the Lakers professional basketball team.


See DTIL sued Soon-Shiong in 2017, wonder what happened to that suit?
https://casetext.com/case/feldman-ex-rel-precision-biologics-inc-v-patrick-soon-shiong-charles-kim-christian-zapf-nantcell-inc

[swampboots]

Emerging new findings on ways to increase the immune response can only ( I assume) benefit CART-T outfits like DTIL.
https://medicalxpress.com/news/2022-07-immune-response-cancer.html

[swampboots]

DTIL: 1.57-1.58 rebuys.

[rtrstock]

Confident here.

[swampboots]

If we all knew what could not stay down we would own a mint.

[rtrstock]

I don't see how this can stay down, too many multi billion dollar companies involved, Novartis! Cargill!

[swampboots]

DTYIL 1.60 ok 1/2 way there.

[swampboots]

I am looking for 1.50 before 2, as I assume it wants to slide but zoom on a nice PR? I am not betting on any riches from DTIL, just dreaming of that prospect.

[rtrstock]

Will this stock split? Noticed it's never split before, no dividend, company should grow, in my opinion, shouldn't this split eventually?

Also, I chose the lend out shares option on robinhood, hope they lend my shares, for passive income, then will reinvest gains back into precision.

I hope this is like buying one of those companies that you hear about people getting rich from, buying at the near inception of the company. Really excited.

[swampboots]

No idea but thought right now should be $5.....to many homespun marks checked.......insider buying, royalty deals with 70K left to settle, cash to 2024, recent dilution offering.they seem vaccinated for $5 now?

[swampboots]

No idea but thought right now should be $5.....to many homespun marks checked.......insider buying, royalty deals with 70K left to settle, cash to 2024, recent dilution offering.they seem vaccinated for $5 now?

[rtrstock]

What could the pps be longterm? They have deals with Cargill, and think crispr is trading at 80.00, what's the potential here?
Zacks has a buy rating, and some predictions put this at a next 52wk high of 14.00-20.00
These seem like good prices now.

This is trading on Nasdaq afterall, plenty of Nasdaq symbols go up.

[swampboots]

DTIL 1.67 should be $5+ , technical chart destruction dictating share price short term.

[swampboots]

DTIL 1.53:
"Live In Play®
Updated: 18-Jul-22 07:37 ET
DTIL: Precision BioSciences received the $50 mln upfront cash payment from Novartis (NVS) under the Collaboration and License Agreement on July 12 (1.42)
The Company expects that as of July 12, 2022, this cash payment, together with its existing cash and cash equivalents, expected operational receipts, and available credit, will be sufficient to fund its operating expenses and capital expenditure to year-end 2024.
Although it has not finalized its full financial results for the quarter ended June 30, 2022, the Company expects to report that it had approximately $184 million in cash and cash equivalents as of June 30, 2022 including receipts of $25 million from Novartis' equity investment in the Company and the June 2022 underwritten offering of the Company's common stock. This amount does not include $50 million in cash received from Novartis subsequent to June 30, 2022."

[swampboots]

DTIL 1.41 sold many gems to add here, close to offering price.!

[jondoeuk]

It should. Simultaneous quad editing of T-cells using BEAM's base editor (CBE; C-to-T) resulted in no detected aberrant karyotypes compared to Cas9* edited cells with the same four gRNAs producing twenty-two aberrant karyotypes (100 cells evaluated).

Based edited cells (again, BEAM's own data) decreased expression of the four targeted genes (efficacy of 94-98% at each target gene), but had only minimal effect on other genes, while Cas9* induced differential expression of over 1,500 genes, including the p53 pathway.

* Keep in mind that CRSP and others continue to enhance their Cas9 systems through protein engineering, as well as identifying optimal gRNAs (both formats and sequences). So an apples to pears comparison.

[swampboots]

DTIL 1.76.

[swampboots]

DTIL 1.67 , been a few days since this level?

[NY1972]

Base editing reminds me of vaccine boosters. It can be done safely every few months with no side effects according to the science gods at NIH. Really?

[swampboots]

"the unintended events" are being reduced each day by
computational and experimental methods that are bringing researchers closer to their goal of revealing exactly where in a cell or tissue each gene is expressed.

[swampboots]

Like the notion selling diminished with flurries of upward jabs.

[swampboots]

"the unintended events" are being reduced each day by
computational and experimental methods that are bringing researchers closer to their goal of revealing exactly where in a cell or tissue each gene is expressed.

[swampboots]

DTIL: this guy has almost" stolen my thoughts:

https://stocktwits.com/schultzeee

[swampboots]

New 13G just filed:

https://www.conferencecalltranscripts.com/summary/?id=11042562

[swampboots]

DTIL 1.53.

Truth be told, I know nothing about the prospects of this stock to yield a net profit.
Insider selling and their funding principle to attract partners, capturing Lilly and Novartis and others already, with more insider buying from their top execs. tilts to me, a higher probable promise than suppositions I could surmise absent those facts.

The video (I linked) however suggests to me, that DTIL is the most promising scalable medical stock I can think of, even if true its ultimate success will lead to complete unfortunate failure.
The idea that this gene editing platform can conceivably be used to be effective for at least 7K diseases is crucial to proclaim its surpassing promise. The rapid new developments in new computational and experimental methods can avail foreseeing continuous increased effectiveness of this platform, even after periods of enduring inconclusive failure.

Bottom line: I can not recommend as a wise investment the stock DTIL,
But when I match DTIL against all possible investments in charitable enterprises, with the expectations of deriving no profit except tax benefits , I think DTIL is also eligible to receive a "philanthropic" donation, with no prospects of a return, except, to just be able to say, when asked to donate money for some disease, the words "I already gave".

Anyway,if anyone can name a stock with more promising scalable prospects than DTIL, it would to the highest degree, tease my curiosity.


Unfollow Board
Keyboard Sh

[jondoeuk]

CART-T versus Crisper, a vocabular of the differences are explored and elaborated, ie. the reduction in unintended events.

Yes, chromosomal abnormalities. From memory, ALLO and CRSP may have said these range in up to a few percent. The former is working on base editing to (greatly) reduce them.

[swampboots]

DTIL early success will allow DTIL to partner with others for the 7K diseases and allow them the honor of paying for all R and D.

[swampboots]

DTIL: at different points in time, could see PR pin ball machine output as
this editing platform has so many explorational aspirational stabs towards enduring cures with an infinity of ways to enhance and modify their first tries with elite collaborative partners..
For example platform may be perfect but DNA edited into wrong target tissue spot, oops must try again this same platform.

[swampboots]

DTIL:

DTIL: CART-T gene editing laboriously explained in this 2 hour video.

Explains why so complicated and expensive, and perhaps a firewall against competitors?

CART-T versus Crisper, a vocabular of the differences are explored and elaborated, ie. the reduction in unintended events.

The transformative aspect as well as this editing platform
theoretically scalability for 7K diseases are shockingly cogently difficult to comprehend as its value would be above the billions, and hit the big T if ideal outcomes are not compromised, for most unmet disease outcomes..

[swampboots]

DTIL : Since Friday 72 hour+ blackout observed, only Swampboots could post on IHUB, regarding a stock which soared 23% today and has symbol DTIL, I deserve this exclusivity!

[swampboots]

DTIL 1.89

[swampboots]

DTIL 1.77 a start!

[swampboots]

DTIL 1.54 crumbs from offering completion PR.

[swampboots]

DTIL: 1.44 price reflects a lack of exposing deep fraud and deception, or misdirection, in the face of these realities and theories:

1- price falling violently from 2 to 1.11 because of a false material influence of another T-Cart editing platform which failed (collateral damage from CRBU data).
2-- DTIL not desperate for cash with 100 million in recurring revenue, and market cap below 100 million, before their additional 50 million underwriting share offering..
3-- Novartis affirming and validating their platform with 75 million
divy and offering 1.4 billion potential milestones.
4- CEO upping his stake by 40% with 30,000 additional share purchase @$2, days ago.
5- 50 million dollar dilutive offering@1.39 throwing off scent to dumb money but ensuring cash runway to 2024.

My theory, a cynical attempt by group to attack share price who believe (correctly) they can capture huge shares for future ante, believing technical vol. price drops rule short term investing predilections, confirming to the mob, that the dictum do not fight the tape is usually the most authoritative source consistent with implementing prudent investing behavior.

Net effect to my brain is that this is a rare "no-brainer" which defies all rules I know about investing in a stock, and a cautionary note to myself not to invest in any BIo stock because I believe in its great science without evidence of massive insider buying and affirmation by one of the top largest pharmaceutical firms with a major investment and alliance.

[jondoeuk]

Speaking of NVS https://www.businesswire.com/news/home/20220621005983/en/Precision-BioSciences-Announces-In-Vivo-Gene-Editing-Collaboration-with-Novartis-to-Develop-Potentially-Curative-Treatment-for-Disorders-Including-Sickle-Cell-Disease

[jondoeuk]

They didn't waste much time! https://www.businesswire.com/news/home/20220621006078/en/Precision-BioSciences-Announces-50-Million-Offering-of-Common-Stock

[swampboots]

DTIL 2.19 after hour spike on news I did not read sold.

[swampboots]

DTIL: Note well
DTIL is no brainer, second after MICS alert a couple of weeks ago, and second after never finding a true live present one I was comfortable to declare.:

See this post which confirms:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169114174

[swampboots]

DTIL added 1.59 on "punk" downgrade to market perform.

[NY1972]

From 10K:
Importantly, our one-step genome editing
approach avoids making multiple breaks to the T cell’s DNA and also contributes to minimizing cell processing time, which helps prevent the
CAR T cells from differentiating during the process.
• Novel co-stimulatory domain. Our genetically engineered CAR T cells incorporate a novel, proprietary, costimulatory domain called N6, which
may enable us to enhance cell proliferation and effector function while preserving cell phenotype. We engineered N6 to improve on the function
of the 4-1bb costimulatory domain commonly used in autologous CAR T products. Our preclinical data suggests that, compared to 4-1bb, N6
provides an activation signal to the CAR T cells that better preserves cell expansion potential while maintaining naïve cell phenotype following
exposure to cancer cells. We also believe N6 can help avoid CAR T cell hyperstimulation, which can contribute to adverse events seen with
autologous products.
This allows us to “fine-tune” the CAR T cells to ensure that they respond appropriately to the cancer but do not become
hyper-activated or exhausted. The below comparison demonstrates the difference in consistency achieved by using lentivirus delivery compared
with targeted delivery through an ARCUS nuclease. CAR T cells produced using ARCUS exhibit reduced cell-to-cell variability as well as more
controlled levels of CAR gene expression depending on whether the cells are tuned for high expression or low expression.